Nortriptyline Hydrochloride Market Assessment, By Purity [Less than 98%, 98%, 98.1% to 99%, More than 99%], By Form [Capsule, Tablet, Others], By Application [Medicine Manufacturing, Research and Academics, Others], By Region, Opportunities and Forecast,

Nortriptyline Hydrochloride Market Assessment, By Purity [Less than 98%, 98%, 98.1% to 99%, More than 99%], By Form [Capsule, Tablet, Others], By Application [Medicine Manufacturing, Research and Academics, Others], By Region, Opportunities and Forecast, 2017-2031F

Global nortriptyline hydrochloride market is projected to witness a CAGR of 2.3% during the forecast period 2024-2031, growing from USD 239.7 million in 2023 to USD 287.52 million in 2031F. The market growth is aided by increasing incidences of nerve pain and the rising prevalence of mood disorders such as depression.

Nortriptyline inhibits the reuptake of norepinephrine and serotonin by the presynaptic neuronal membrane, resulting in an increased concentration of these neurotransmitters in the synapse. Nortriptyline also inhibits the activity of acetylcholine, histamine, and 5-hydroxytryptamine. The increasing prevalence of depression in various regions around the globe is one of the major market trends that is fostering market growth. For instance, according to the estimates of the World Health Organization (WHO), approximately 5% of the adult global population suffers from depression. It is 50% more common in women as compared to men. This increase in the number of individuals suffering from depression will provide lucrative growth opportunities to the market as nortriptyline hydrochloride, an active metabolite of amitriptyline acts as a tricyclic antidepressant and is used for treating major depression.

The rise in incidences of individuals suffering from neuropathic pain is another major factor bolstering the global nortriptyline hydrochloride market size. Nortriptyline reduces neuropathic pain by increasing noradrenaline levels that act within the dorsal root ganglia on β2-adrenoceptors expressed by the non-neuronal satellite cells. Stimulating β2-adrenoceptors results in the reduced neuropathy-induced production of TNFα, thereby relieving neuropathic pain. Nortriptyline is usually administered orally as a solution or a capsule. The capsule is available in varying strengths including 75 mg, 50 mg, 25 mg, and 10 mg and the solution is available in the composition of 10mg/ 5mL (473 mL). Hence, due to the increasing cases of individuals suffering from neuropathic pain, the requirement for nortriptyline hydrochloride is rising to support the production of medication for pain management, thereby providing lucrative growth opportunities to the market.

Growing Prevalence of Depression Supports Global Nortriptyline Hydrochloride Market Growth

The nortriptyline hydrochloride treats depression by increasing the quantity of norepinephrine and serotonin in the brain, the substances that are responsible for regulating mood. Thus, supporting the market's growth by propelling the demand for nortriptyline hydrochloride. The dosage of the medication is based on the condition of the patient and their response to the treatment. The dose of the medication is directed at a lower range which is then increased gradually to reduce the risk of side effects associated with the medication.

The susceptibility of the contemporary population to depression is growing due to several factors including intense individual competitiveness, rising social failure, low social support, and increased inequality. For instance, according to the estimates of the World Health Organization (WHO), approximately 3.8% of the population suffers from depression. This includes 5% of the adult population of which 5.7% are older than 60 years. Nearly 280 million individuals across the globe are living with depression. Hence, this increase will augment the requirement for nortriptyline hydrochloride as the product belongs to a group of medications that are known as tricyclic antidepressants.

Increasing Incidences of Diabetic Neuropathy Boosts Global Nortriptyline Hydrochloride Market Demand

The presence of high blood glucose levels and fats, including triglycerides in blood due to diabetes can result in nerve damage causing diabetic neuropathy. High blood sugar levels can also cause damage to the blood vessels that provide the nerves with nutrients and oxygen. For instance, according to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 30% of the individuals suffering from diabetes have automatic neuropathy. This, in turn, is bolstering the requirement for nortriptyline hydrochloride to support the production of medication for managing diabetic neuropathy. Henceforth, augmenting the market demand in various regions across the globe.

Meanwhile, the rising consumption of food products with high amounts of sugar and carbonated beverages coupled with changing lifestyle patterns are increasing the number of individuals suffering from diabetes. This, in turn, is propelling the incidences of diabetic neuropathy, bolstering the product demand to ensure the production of appropriate medication to support the management of the condition. For instance, according to the projections of the International Diabetes Federation, by 2045, approximately 783 million people, 1 in 8 adults, will be living with diabetes. As the incidences of diabetes increase, the cases of diabetic neuropathy will also increase, thus augmenting the global nortriptyline hydrochloride market growth.

North America Accounts for Significant Market Share

The presence of a well-established healthcare sector and increasing investments by various pharmaceutical, healthcare, and biotechnology companies towards research and development activities is bolstering the demand for nortriptyline hydrochloride in various countries in North America. The increasing prevalence of depression in the region is further supporting the market expansion. For instance, according to the estimates of Mental Health America, more than 8% of American adults, approximately 21 million individuals are affected by depression. This increased prevalence coupled with the easy accessibility to various medications that help in treating depression are supporting the market growth as nortriptyline hydrochloride works as a tricyclic antidepressant. Therefore, the increasing incidences of individuals suffering from chronic pain is another major factor supporting the market expansion in the region, as the product finds applications in various medications that are used for treating chronic pain.

Rising Demand for More than 99% Nortriptyline Hydrochloride Boosts Market Growth

The increasing requirement for nortriptyline hydrochloride with more than 99% purity can be attributed to their rising demand by academic and research institutions and medicine manufacturing facilities in various regions across the globe. The pharmaceutical sector is significantly growing in various regions, for instance, according to the estimates of The Association of the British Pharmaceutical Industry, the pharmaceutical industry spends approximately USD 160 billion every year on research and development activities as the development of novel medications involves significant rates of failure. Due to such growing efforts and investments in medicine manufacturing, the requirement for nortriptyline hydrochloride will increase, thus propelling the growth of the market. The preference for nortriptyline hydrochloride with more than 99% purity can also be attributed to the high efficacy offered by the product as opposed to their counterparts, thus augmenting their demand, and supporting the expansion of the market.

Capsules Account for Significant Global Nortriptyline Hydrochloride Market Share

The expansion of the segment can be attributed to the higher bioavailability offered by the capsules as opposed to their counterparts, making them more effective than tablets. The nortriptyline hydrochloride capsules contain various inactive ingredients including sodium lauryl sulfate, colloidal silicon dioxide, pregelatinized starch, and magnesium stearate. For instance, the 75 mg, 50 mg, 25 mg, and 10 mg capsule shells contain titanium dioxide, gelatin, sodium lauryl sulfate, propylparaben, and methylparaben. They can also contain edetate calcium disodium, benzyl alcohol, silicon dioxide or sodium propionate, and butylparaben. The 75 mg, 25 mg, and 10 mg capsule shells also contain FD&C Blue No. 1 and D&C Yellow No. 10. The nortriptyline hydrochloride is usually prescribed for the smallest quantity of capsules with good patient management, to reduce the risk of overdose. Thus, the increased accessibility to nortriptyline hydrochloride capsules coupled with the rising awareness about mental health and depression are supporting the growth of the segment, thus boosting the market expansion.

Future Market Scenario (2024–2031F)

According to the global nortriptyline hydrochloride market analysis, the demand for nortriptyline hydrochloride will increase over the forecast period due to increasing research and development activities and utilization of the product for drug repurposing. Various studies are being conducted to evaluate the potential candidacy of nortriptyline hydrochloride for repurposing of drugs. For instance, according to an article published by researchers from the Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China, nortriptyline hydrochloride exhibits significant antitumor activities in both in-vitro and in-vivo. The product can inhibit gastric cancer by inducing oxidative stress and apoptosis. Conduction of such studies will bolster the requirement for nortriptyline hydrochloride over the forecast period by academic and research institutions augmenting the market demand.

Key Players Landscape and Outlook

The companies are undergoing continuous research and development. Furthermore, they are collaborating with other companies and organizations to support their R&D activities. Such initiatives will provide lucrative growth opportunities for the market as at times such efforts bring economies of scope that would not have been possible through organic growth. Thus, supporting the expansion of the global nortriptyline hydrochloride market.

In October 2023, Viatris Inc., one of the leading healthcare and pharmaceutical corporations, announced that they would be selling their Active Pharmaceutical Ingredients (API) business to Iquest Enterprises. The transaction includes a research and development lab and three manufacturing sites in Hyderabad, third-party API sales, and three manufacturing sites in Vizag.